Results 71 to 80 of about 556,889 (346)

β‐1,3 Glucan Microparticles & Nanoparticles: Fabrication Methods & Applications in Immunomodulation & Targeted Drug Delivery

Advanced Healthcare Materials, EarlyView.
Beta‐glucans have gained significant attention as an immunomodulatory biomaterial with cell‐targeting capabilities. This review comprehensively outlines the design and fabrication methods for producing beta‐glucan particles at both the micro and nanoscale and their applications in immune cell targeting, immunomodulation, and drug delivery ...
Nate Dowdall, Todd Hoare
wiley   +1 more source

Glucose-6 Phosphate, A Central Hub for Liver Carbohydrate Metabolism

Metabolites, 2019
: Cells efficiently adjust their metabolism according to the abundance of nutrients and energy. The ability to switch cellular metabolism between anabolic and catabolic processes is critical for cell growth.
Fabienne Rajas, Amandine Gautier-Stein, Gilles Mithieux   +2 more
doaj   +1 more source

Newborn Screening for Pompe Disease

International Journal of Neonatal Screening, 2020
Glycogen storage disease type II (also known as Pompe disease (PD)) is an autosomal recessive disorder caused by defects in α-glucosidase (AαGlu), resulting in lysosomal glycogen accumulation in skeletal and heart muscles.
Takaaki Sawada, Jun Kido, Kimitoshi Nakamura   +2 more
doaj   +1 more source

Clinical, Biochemical and Molecular Characterization of a Cohort of Glycogen Storage Disease Type I Patients in a High Complexity Hospital in Argentina

Journal of Inborn Errors of Metabolism and Screening, 2021
Glycogen storage disease type I is an autosomal recessive disorder of carbohydrate metabolism that manifests mainly by hepatomegaly and hypoglycemia with short fasts. Despite strict therapy, patients present long-term renal and liver complications.
Verónica Bindi, Hernán D. Eiroa, Carolina Crespo, María Martinez, Luisa Bay   +4 more
doaj   +1 more source

Opportunities in Therapeutic mRNA Stabilization: Sequence, Structure, Adjuvants and Vectors

Advanced Therapeutics, EarlyView.
Current mRNA lipid nanoparticles rely on cold storage, which increases the cost and reduces access to the vaccines. As mRNA expands to other clinical opportunities, better methods to stabilize the medicines during shipping, storage, and delivery are needed.
Joshua A. Choe, Jacobus Burger, Jamie Jones, Apurva Panjla, William L. Murphy   +4 more
wiley   +1 more source

DBS Screening for Glycogen Storage Disease Type 1a: Detection of c.648G>T Mutation in G6PC by Combination of Modified Competitive Oligonucleotide Priming-PCR and Melting Curve Analysis

International Journal of Neonatal Screening, 2021
Glycogen storage disease type Ia (GSDIa) is an autosomal recessive disorder caused by glucose-6-phosphatase (G6PC) deficiency. GSDIa causes not only life-threatening hypoglycemia in infancy, but also hepatocellular adenoma as a long-term complication ...
Emma Tabe Eko Niba, Yogik Onky Silvana Wijaya, Hiroyuki Awano, Naoko Taniguchi, Yasuhiro Takeshima, Hisahide Nishio, Masakazu Shinohara   +6 more
doaj   +1 more source

A Compound Screen Based on Isogenic hESC‐Derived β Cell Reveals an Inhibitor Targeting ZnT8‐Mediated Zinc Transportation to Protect Pancreatic β Cell from Stress‐Induced Cell Death

Advanced Science, EarlyView.
Pancreatic β cell loss by cellular stress contributes to diabetes pathogenesis. The study demonstrates that WFS1–ZnT8–zinc axis regulates vicious cycle of zinc transportation and cellular stress in pancreatic β cell. Based on that, the study applies a strategy for compound screening targeting ZnT8 based on human models, and identifies anisomycin, as a ...
Rui Hu, Qing Ma, Yunhui Kong, Zhaoyue Wang, Minglu Xu, Xiangyi Chen, Yajuan Su, Tinghui Xiao, Qing He, Xuan Wang, Wenjun Xu, Yiling Yang, Xushu Wang, Xiaobo Li, Yanfang Liu, Shuangshuang Chen, Rui Zhao, Meng Guo, Gaowei Wang, Weida Li   +19 more
wiley   +1 more source

Glycogen storage diseases with liver involvement: a literature review of GSD type 0, IV, VI, IX and XI

Orphanet Journal of Rare Diseases, 2022
Background Glycogen storage diseases (GSDs) with liver involvement are classified into types 0, I, III, IV, VI, IX and XI, depending on the affected enzyme.
Miriam Massese, Francesco Tagliaferri, Carlo Dionisi-Vici, Arianna Maiorana   +3 more
doaj   +1 more source

Alzheimer's disease: a mathematical model for onset and progression [PDF]

Math. Med. Biol., 34(2):193-214, 2017, 2015
In this paper we propose a mathematical model for the onset and progression of Alzheimer's disease based on transport and diffusion equations. We regard brain neurons as a continuous medium, and structure them by their degree of malfunctioning. Two different mechanisms are assumed to be relevant for the temporal evolution of the disease: i) diffusion ...
arxiv   +1 more source

Sugar‐sensing swodkoreceptors and swodkocrine signaling

Animal Models and Experimental Medicine, EarlyView.
Sugar‐sensing swodkoreceptors that trigger swodkocrine signaling. Abstract Sugars are one of the major metabolites and are essential for nucleic acid synthesis and energy production. In addition, sugars can act as signaling molecules. To study sugar signaling at the systemic level, there is an urgent need to systematically identify sugar‐sensing ...
Savani Anbalagan
wiley   +1 more source